Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Recent Advances in the Diagnosis of Alzheimer's Disease: A Brief Overview of Tau Pet Tracers in Nuclear Medicine Publisher Pubmed



Aghahosseini F1 ; Salehi Y1, 2 ; Farzanefar S1 ; Kashi MB1 ; Eppard E3, 4 ; Ahmadzadehfar H5 ; Mirzaei S6 ; Vahidfar N1 ; Aghanejad A7, 8
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Nuclear Medicine, Vali-Asr Hospital, Tehran University of Medical Sciences, Iran
  2. 2. Research Center for Nuclear Medicine, Tehran University of Medical Sciences, Tehran, Iran
  3. 3. Positronpharma SA, Santiago, 7500621, Chile
  4. 4. Department of Nuclear Medicine, University Hospital Magdeburg, Leipziger Strass 44, Magdedurg, 39120, Germany
  5. 5. Department of Nuclear Medicine, Klinikum Westfalen, Dortmund, 44309, Germany
  6. 6. Klinik Ottakring, Institute of Nuclear Medicine with PET-Center, Vienna, 1220, Austria
  7. 7. Research Center for Pharmaceutical Nanotechnology, Biomedicine Institute, Tabriz University of Medical Sciences, Tabriz, Iran
  8. 8. Department of Nuclear Medicine, Faculty of Medicine, Imam Reza General Hospital, Tabriz University of Medical Sciences, Tabriz, Iran

Source: Current Radiopharmaceuticals Published:2025


Abstract

Dementia (the most common cause of Alzheimer's disease) is defined as a chronic or progressive syndrome with disturbance of multiple cortical functions, the most important of them including memory, learning capacity, comprehension, orientation, calculation, language, and judgement. These cognitive impairments affect the quality of life, behavior, and social relations. Techniques of nuclear medicine provide feasible ways to record the intracellular alterations of disease and deficiencies. In these non-invasive manners, the hippocampal-neocortical disconnection may partly explain the hypo-metabolism incident found in Alzheimer's disease. Based on this fact, the study of all these mechanisms of action is conceivable and achievable by radiopharmaceuticals. This review is aimed at the presentation of radiopharmaceuticals that are developed for the detection of Alzheimer’s disease in preclinical and clinical trials. © 2025 Bentham Science Publishers.